JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Using VR to Assess the Efficacy of a Motivational Interviewing Intervention to Increase Bystander Behaviors

  NCT04160702

  Condition:   Sexual Assault
  Intervention:   Behavioral: Motivate-The-Bystander (MTB)
  Sponsors:   University of Nebraska Lincoln;   University of Nebraska
  Recruiting
• Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

  NCT04138836

  Condition:   Healthy Participants
  Interventions:   Drug: BBT-877;   Drug: Midazolam;   Drug: Itraconazole;   Drug: Esomeprazole
  Sponsors:   Bridge Biotherapeutics, Inc.;   KCRN Research, LLC
  Active, not recruiting
• A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OTAP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

  NCT04121078

  Condition:   Healthy Volunteers
  Interventions:   Drug: TAK-906;   Drug: Rifampin
  Sponsor:   Millennium Pharmaceuticals, Inc.
  Completed
• Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

  NCT04092712

  Condition:   Healthy Volunteers
  Intervention:   Drug: [14C]-CTP-543
  Sponsors:   Concert Pharmaceuticals;   Celerion
  Completed
• Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

  NCT04044339

  Condition:   Healthy
  Interventions:   Drug: TD-5202;   Drug: Placebo
  Sponsor:   Theravance Biopharma
  Recruiting
• Comparison of a Non-linear Analysis of Balance During the mBESS to the Sway Balance Application

  NCT03994952

  Condition:   Healthy Volunteers
  Interventions:   Device: Sway Balance Application;   Device: Balance Tracking Systems
  Sponsor:   University of Nebraska
  Recruiting
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

  NCT03830125

  Condition:   Idiopathic Pulmonary Fibrosis
  Interventions:   Drug: BBT-877, Single dose;   Drug: Placebo group;   Drug: BBT-877, Multiple doses
  Sponsors:   Bridge Biotherapeutics, Inc.;   KCRN Research, LLC
  Recruiting
• Resistance Exercise and Protein During Weight Loss

  NCT03600311

  Conditions:   Weight Loss;   Starvation
  Interventions:   Other: Caloric Restriction;   Dietary Supplement: Post-Exercise Protein;   Other: Energy Balance;   Dietary Supplement: Post-Exercise Carbohydrate;   Dietary Supplement: Calcium and Vitamin D
  Sponsor:   University of Nebraska Lincoln
  Completed
• To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers

  NCT03543137

  Condition:   Tobacco Use Disorder
  Interventions:   Drug: Nicotine Prototype Mini lozenge;   Drug: Nicorette Mini Lozenge
  Sponsor:   GlaxoSmithKline
  Completed
• Finances First: A Health Intervention in Low Income Single Mother Households

  NCT03035240

  Condition:   Financial Stress
  Intervention:   Behavioral: Financial Education
  Sponsor:   Creighton University
  Recruiting
• TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

  NCT02772159

  Condition:   Chronic Obstructive Pulmonary Disease (COPD)
  Intervention:   Drug: TD-4208
  Sponsor:   Theravance Biopharma
  Completed
• Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center

  NCT02409147

  Condition:   Uterus Transplant
  Intervention:   Procedure: Uterine Transplant
  Sponsor:   University of Nebraska
  Withdrawn
• A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

  NCT02288481

  Condition:   Tuberculosis
  Interventions:   Drug: TBA-354;   Other: Placebo
  Sponsor:   Global Alliance for TB Drug Development
  Completed
• PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

  NCT02216331

  Condition:   Tuberculosis
  Interventions:   Drug: TMC207;   Drug: rifapentine;   Drug: rifampicin
  Sponsor:   Global Alliance for TB Drug Development
  Completed
• Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)

  NCT01830439

  Condition:   Tuberculosis
  Interventions:   Drug: PA-824 200mg;   Drug: PA-824 50mg
  Sponsor:   Global Alliance for TB Drug Development
  Completed
• Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam

  NCT01768273

  Condition:   Tuberculosis
  Interventions:   Drug: Midazolam;   Drug: PA-824
  Sponsor:   Global Alliance for TB Drug Development
  Completed
• Pilot Study- Treat to Target Vitamin D in End Stage Renal Disease

  NCT04167111

  Condition:   Chronic Kidney Diseases
  Intervention:   Dietary Supplement: Cholecalciferol
  Sponsors:   University of Nebraska;   University of Nebraska, Omaha
  Not yet recruiting
• Uphill Walking as Exercise for COPD Patients

  NCT04026529

  Condition:   Chronic Obstructive Pulmonary Disease
  Intervention:   Other: walking on incline or walking at increasing speed
  Sponsors:   VA Office of Research and Development;   University of Nebraska, Omaha
  Not yet recruiting
• A Study to Assess Tobacco-related Biomarkers of Exposure in Smokers Using myBlu E-cigarettes

  NCT04019626

  Condition:   Healthy Volunteers
  Interventions:   Other: Continue-smoking;   Other: myblu Tobacco Chill 2.5%;   Other: myblu Tobacco Chill 4.0%;   Other: myblu Honeymoon 2.5%;   Other: myblu Honeymoon 4.0%
  Sponsor:   Fontem Ventures BV
  Recruiting
• Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE

  NCT03998176

  Condition:   HIV-1-infection
  Intervention:   Drug: Bictegravir/emtricitabine/tenofovir alafenamide
  Sponsors:   University of Nebraska;   Gilead Sciences
  Recruiting
• Evaluation of the Spry Belt for Improving Bone Quality

  NCT03986203

  Condition:   Osteopenia
  Intervention:   Device: Spry Belt
  Sponsors:   Theranova, L.L.C.;   National Institute on Aging (NIA);   University of Nebraska
  Recruiting
• A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

  NCT03961295

  Condition:   Healthy Volunteers
  Intervention:   Drug: Vedolizumab SC
  Sponsor:   Takeda
  Completed
• Impact of Evolocumab in Cardiac Transplant Patients With CAV

  NCT03944577

  Condition:   Heart Transplant
  Intervention:   Drug: Evolocumab (Repatha)
  Sponsors:   University of Nebraska;   Amgen
  Recruiting
• ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

  NCT03932643

  Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
  Intervention:   Drug: ONC201
  Sponsor:   Vijaya Bhatt
  Recruiting
• Restoring Cognitive Control in Acute Nicotine Withdrawal

  NCT03887429

  Condition:   Impulse Control Disorders
  Interventions:   Drug: SXC-2023;   Drug: Placebos
  Sponsors:   Promentis Pharmaceuticals, Inc.;   Baylor College of Medicine;   Celerion
  Completed
• Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

  NCT03858075

  Condition:   Healthy Volunteers
  Interventions:   Drug: BLU-782;   Drug: Placebo;   Drug: BLU-782 taken with food
  Sponsor:   Blueprint Medicines Corporation
  Completed
• Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

  NCT03790670

  Condition:   Parkinson Disease
  Intervention:   Drug: sargramostim
  Sponsor:   University of Nebraska
  Active, not recruiting
• Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience

  NCT03724331

  Conditions:   Fatigue;   Self Efficacy;   Quality of Life;   Physical Activity;   Lung Cancer;   Non-Small Cell Lung Cancer
  Interventions:   Behavioral: Light Physical Activity 1;   Behavioral: Light Physical Activity 2;   Behavioral: Support Education Activity
  Sponsors:   University of Nebraska;   Spectrum Health Hospitals;   Ingham Regional Medical Center;   Sparrow Clinical Research Institute;   Munson Medical Center
  Recruiting
• Effect of Vitamin D Supplementation on Balance in CKD

  NCT03710161

  Conditions:   Renal Insufficiency, Chronic;   Kidney Failure, Chronic
  Intervention:   Drug: Vitamin D
  Sponsor:   University of Nebraska
  Recruiting
• Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention

  NCT03662295

  Conditions:   Migraine Disorders;   Aphasia
  Intervention:   Behavioral: Language treatment
  Sponsor:   Quality Living, Inc.
  Completed
• Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities

  NCT03574207

  Conditions:   Mild Cognitive Impairment;   Memory Loss
  Intervention:   Device: Transcranial magnetic stimulation
  Sponsors:   University of Nebraska;   National Institute of General Medical Sciences (NIGMS)
  Recruiting
• Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

  NCT03476174

  Condition:   Melanoma
  Interventions:   Drug: Pembrolizumab;   Drug: Interleukin-2
  Sponsors:   Ralph Hauke;   Nebraska Cancer Specialists; Midwest Cancer Center-Legacy;   Prometheus Laboratories
  Terminated
• Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer

  NCT03386500

  Conditions:   Anal Cancer, Squamous Cell Carcinoma;   Radiation Exposure
  Intervention:   Drug: BMX-001
  Sponsors:   Chi Lin, MD;   BioMimetix JV, LLC;   University of Nebraska
  Recruiting
• Engaging Rural Men With Mobile Technologies for Weight Loss

  NCT03329079

  Condition:   Weight Loss
  Interventions:   Behavioral: Mobile Technology Plus;   Behavioral: Mobile Technology
  Sponsors:   University of Nebraska;   Northeast Nebraska Public Health Department
  Active, not recruiting
• Language Assessment and Treatment Following Acquired Brain Injury

  NCT03320954

  Condition:   Brain Injuries
  Intervention:   Behavioral: Anomia treatment
  Sponsor:   University of Nebraska Lincoln
  Completed
• Preventing Diabetes With Digital Health and Coaching

  NCT03312764

  Condition:   PreDiabetes
  Interventions:   Behavioral: Online diabetes prevention program;   Behavioral: Standard Care
  Sponsors:   Omada Health, Inc.;   University of Nebraska;   Wake Forest University Health Sciences
  Active, not recruiting
• Impact of Oral Hygiene Gels on Peri-implant Mucositis

  NCT03243591

  Condition:   Mucositis
  Interventions:   Other: Livionex gel;   Other: Aquafresh gel
  Sponsor:   University of Nebraska
  Completed
• Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia

  NCT03226418

  Conditions:   Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
  Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Azacitidine;   Drug: Venetoclax;   Drug: glasdegib
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Recruiting
• Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

  NCT03198767

  Condition:   Obesity
  Interventions:   Drug: LIK066;   Dietary Supplement: Carbohydrate 50%;   Dietary Supplement: Carbohydrate 25%;   Dietary Supplement: Carbohydrate 8%;   Dietary Supplement: Carbohydrate 0%;   Dietary Supplement: Psyllium;   Dietary Supplement: Calcium carbonate
  Sponsor:   Novartis Pharmaceuticals
  Completed
• Early Rheumatoid Arthritis Lung Disease Study

  NCT03192267

  Condition:   Rheumatoid Arthritis
  Intervention:  
  Sponsor:   University of Nebraska
  Recruiting
• Intensive Referral to Reduce Smoking in Probationers

  NCT03042650

  Conditions:   Smoking Cessation;   Substance Use Disorder
  Interventions:   Behavioral: Intensive Referral Intervention Group;   Behavioral: Standard Practice Facilitated Group
  Sponsor:   University of Nebraska
  Active, not recruiting
• Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients

  NCT03039569

  Condition:   Diabetes Mellitus, Type 2
  Intervention:   Behavioral: Text messaging
  Sponsors:   University of Nebraska Lincoln;   The Methodist Hospital System
  Completed
• TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT02874404

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
  Interventions:   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: PI3K-delta Inhibitor TGR-1202
  Sponsors:   Matthew Lunning, DO;   National Cancer Institute (NCI)
  Completed
• Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

  NCT02833701

  Conditions:   Glioblastoma;   Glioma
  Interventions:   Dietary Supplement: Ascorbic Acid;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Terminated
• Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery

  NCT02767388

  Conditions:   Myelodysplastic Syndrome;   Effects of Chemotherapy;   Mild Cognitive Impairment;   Multiple Myeloma;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphoid Leukemia;   Chronic Myeloid Leukemia;   Acute Myeloid Leukemia
  Intervention:  
  Sponsor:   University of Nebraska
  Completed
• Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia

  NCT02647892

  Condition:   Local Anesthesia
  Interventions:   Drug: lidocaine;   Drug: sodium bicarbonate
  Sponsor:   University of Nebraska
  Enrolling by invitation
• Cholecalciferol in Treating Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency

  NCT02553447

  Conditions:   Chronic Lymphocytic Leukemia;   Non-Hodgkin Lymphoma;   Untreated Chronic Lymphocytic Leukemia;   Vitamin D Deficiency
  Interventions:   Dietary Supplement: Cholecalciferol;   Other: Laboratory Biomarker Analysis
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Recruiting
• Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12-36 Months of Age With Serologic Evidence of Prior Exposure

  NCT04144348

  Condition:   Human Metapneumovirus and Human Parainfluenza Infection
  Interventions:   Biological: mRNA-1653;   Biological: Placebo
  Sponsor:   ModernaTX, Inc.
  Recruiting
• Phase 1 Study of ACE-083 in Healthy Subjects

  NCT02257489

  Condition:   Musculoskeletal Diseases
  Intervention:   Drug: ACE-083
  Sponsor:   Acceleron Pharma, Inc.
  Completed
• Measurement of Beta Cell Death in Individuals With Cystic Fibrosis

  NCT03713437

  Condition:   Cystic Fibrosis-related Diabetes
  Intervention:   Diagnostic Test: Measurement of differentially methylated insulin DNA
  Sponsors:   University of Nebraska;   Cystic Fibrosis Foundation
  Recruiting
• Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer

  NCT01959672

  Conditions:   Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma;   Stage I Pancreatic Cancer;   Stage IA Pancreatic Cancer;   Stage IB Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
  Interventions:   Procedure: 4-Dimensional Computed Tomography;   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Nelfinavir Mesylate;   Biological: Oregovomab;   Radiation: Stereotactic Body Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Completed
• A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

  NCT03574584

  Conditions:   Metabolism and Nutrition Disorders;   Overweight or Obesity
  Interventions:   Drug: NNC0165-1562;   Drug: Semaglutide;   Drug: Placebo (NNC0165-1562)
  Sponsor:   Novo Nordisk A/S
  Completed
• Effects of Octacosanol During Taekwondo Training

  NCT03557476

  Conditions:   Oxidative Stress;   Dyslipidemias
  Interventions:   Dietary Supplement: Octacosanol;   Dietary Supplement: Placebo
  Sponsor:   University of Nebraska, Omaha
  Completed
• Mobility Exercises for Gait (MEG Neuroplasticity Project)

  NCT03555708

  Condition:   Cerebral Palsy
  Intervention:   Other: Physical Therapy
  Sponsor:   University of Nebraska
  Recruiting
• Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp

  NCT01930539

  Conditions:   Vitamin D Deficiency;   Short Bowel Syndrome
  Intervention:   Device: Ultraviolet B lamp
  Sponsor:   University of Nebraska
  Completed
• Resurgence as Choice: Basic and Clinical Studies

  NCT03423940

  Conditions:   Increasing Functional Communicative Behavior;   Decreasing Destructive Behavior;   Analysis of Treatment Dosage;   Empirically Determined Reinforcement Schedule Thinning
  Interventions:   Behavioral: Functional communication training;   Behavioral: RaC-enhanced functional communication training
  Sponsors:   University of Nebraska;   Utah State University
  Recruiting
• Feasibility of a Touch Screen Computer Based Breast-feeding Educational Support Program

  NCT03308058

  Condition:   Pregnancy Related
  Intervention:   Behavioral: Breastfeeding computer education
  Sponsor:   University of Nebraska
  Completed
• Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer

  NCT01307956

  Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Adenocarcinoma;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer
  Interventions:   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Panitumumab;   Other: Pharmacological Study;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Terminated
• Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control

  NCT02483572

  Conditions:   Aggression;   Self-Injurious Behavior
  Intervention:   Behavioral: Functional Communication Training
  Sponsor:   University of Nebraska
  Terminated
• Stereotactic Radiation Therapy, Nelfinavir Mesylate, Gemcitabine Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Locally Advanced Pancreatic Cancer

  NCT01068327

  Conditions:   Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer
  Interventions:   Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Drug: nelfinavir mesylate;   Radiation: stereotactic body radiation therapy;   Radiation: hypofractionated radiation therapy;   Procedure: therapeutic conventional surgery
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Completed
• Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women

  NCT01052051

  Condition:   Cancer
  Interventions:   Dietary Supplement: Vitamin D3;   Dietary Supplement: Calcium carbonate
  Sponsors:   Creighton University;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
  Completed
• Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

  NCT00856037

  Condition:   Recurrent Small Cell Lung Carcinoma
  Interventions:   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Drug: Topotecan Hydrochloride
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Completed
• Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders

  NCT01867398

  Conditions:   Conduct Disorder;   fMRI
  Intervention:  
  Sponsors:   National Institute of Mental Health (NIMH);   Boys Town Research Hospital
  Terminated
• Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

  NCT00626366

  Condition:   Chronic Sinusitis
  Interventions:   Radiation: Sinus CT Scan;   Drug: Omnipaque 240 Contrast Solution;   Drug: Omnipaque 240 mg I/mL
  Sponsor:   University of Nebraska
  Completed
• CT Scans in Screening for Lung Cancer in Current and Former Smokers

  NCT00625690

  Condition:   Lung Cancer
  Interventions:   Other: questionnaire administration;   Procedure: computed tomography;   Procedure: evaluation of cancer risk factors;   Procedure: study of high risk factors
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Completed
• Role of Apathy in the Effectiveness of Weight Loss Interventions

  NCT00548652

  Conditions:   Obesity;   Apathy
  Interventions:   Behavioral: MOVE;   Behavioral: medical crisis councelling;   Drug: methyphenidate
  Sponsor:   VA Nebraska Western Iowa Health Care System
  Completed
• Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

  NCT00089024

  Condition:   Pancreatic Cancer
  Interventions:   Drug: fluorouracil;   Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Completed
• Validity of Physical Activity Questionnaires in Persons Pursuing Bariatric Surgery

  NCT03981978

  Conditions:   Bariatric Surgery Candidate;   Obesity
  Intervention:   Behavioral: Physical Activity
  Sponsor:   University of Nebraska
  Not yet recruiting
• Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic

  NCT03431831

  Condition:   Obesity
  Interventions:   Behavioral: Intervention Control;   Behavioral: Counselling;   Drug: Contrave;   Drug: Contrave and Counseling
  Sponsor:   University of Nebraska
  Active, not recruiting
• CALLiNGS Protocol: Care Across Locations Longitudinally in Navigation of Goals and Symptoms

  NCT03999957

  Condition:   Palliative Care
  Intervention:   Other: Telehealth web conferencing
  Sponsor:   University of Nebraska
  Recruiting
• Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

  NCT01994174

  Condition:   Macular Disease
  Intervention:  
  Sponsor:   University of Nebraska
  Recruiting
• Bupropion in the Treatment of Methamphetamine Dependence

  NCT00572234

  Condition:   Methamphetamine Use Disorder
  Intervention:   Drug: bupropion SR
  Sponsor:   University of Nebraska
  Completed
• First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age

  NCT01365884

  Condition:   Refractive Error
  Intervention:  
  Sponsor:   University of Nebraska
  Terminated
• Pain Management Following Sinus Surgery

  NCT03822962

  Conditions:   Nasal Sinus; Inflammation;   Opioid Abuse;   Pain, Postoperative
  Interventions:   Drug: Ibuprofen 600Mg Tablet;   Other: Standard Regimen | Tylenol
  Sponsor:   University of Nebraska
  Recruiting
• A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

  NCT03961308

  Condition:   Healthy Volunteers
  Intervention:   Drug: Vedolizumab SC
  Sponsor:   Takeda
  Completed
• Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery

  NCT02654119

  Conditions:   HER2 Positive Breast Carcinoma;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Biological: Trastuzumab
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Active, not recruiting
• An Ascending Dose Comparison of MVT-100 to Definity in Healthy Volunteers

  NCT03882359

  Condition:   Heart Diseases
  Interventions:   Diagnostic Test: Echocardiogram;   Drug: MVT-100;   Drug: Definity
  Sponsors:   Microvascular Therapeutics, LLC;   National Heart, Lung, and Blood Institute (NHLBI);   University of Nebraska
  Recruiting
• Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

  NCT03737123

  Condition:   Urothelial Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Gemcitabine;   Drug: Atezolizumab;   Drug: Docetaxel
  Sponsors:   Nabil Adra;   Genentech, Inc.;   Indiana University School of Medicine
  Recruiting
• Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT02524275

  Condition:   Head and Neck Squamous Cell Carcinoma
  Interventions:   Drug: Capecitabine;   Drug: Docetaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   University of Nebraska
  Recruiting
• Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

  NCT03007979

  Conditions:   Breast Cancer;   Breast Carcinoma;   Cancer of Breast;   Malignant Tumor of Breast
  Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Procedure: Optional research biopsy;   Drug: Goserelin;   Procedure: Research blood draw;   Procedure: Circulating tumor cell blood draw;   Procedure: Tumor biopsy (optional)
  Sponsors:   Washington University School of Medicine;   Pfizer
  Recruiting
• 12 Weeks of Resistance Band Exercise Impacts on Metabolic Syndrome Progression in Postmenopausal Women

  NCT04014686

  Conditions:   Metabolic Syndrome;   Dyslipidemias;   Insulin Resistance;   Hypertension
  Interventions:   Other: No exercise intervention group;   Behavioral: Resistance band exercise intervention group
  Sponsor:   Pusan National University
  Completed
• Study on Physical Activity's Relationship With Cancer and Cognition

  NCT03980626

  Conditions:   Breast Cancer;   Breast Neoplasm Female
  Intervention:   Behavioral: Walking
  Sponsor:   University of Nebraska
  Recruiting
• Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO

  NCT03673566

  Conditions:   Preterm Birth;   Low; Birthweight, Extremely (999 Grams or Less);   Neonatal Infection;   Satisfaction;   Stress;   Chronic Lung Disease;   Growth Acceleration;   Adverse Event
  Intervention:   Device: NICU Dashboard
  Sponsors:   Philips Healthcare;   Children's Hospital and Medical Center, Omaha, Nebraska
  Recruiting
• Treatment for Reading and Writing Deficits Following Acquired Brain Injury

  NCT03662243

  Conditions:   Acquired Brain Injury;   Alexia;   Agraphia
  Intervention:   Behavioral: Multicomponent reading and writing treatment
  Sponsor:   Quality Living, Inc.
  Enrolling by invitation
• Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.

  NCT03186378

  Condition:   Molluscum Contagiosum
  Intervention:   Combination Product: VP-102 with applicator
  Sponsors:   Verrica Pharmaceuticals Inc.;   Paidion Research, Inc.;   Database Integrations, Inc.;   Cato Research;   Instat services
  Completed
• Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis

  NCT03010228

  Condition:   Lyme Borreliosis, Nervous System
  Interventions:   Biological: VLA15 with Alum;   Biological: VLA15 without Alum
  Sponsor:   Valneva Austria GmbH
  Completed
• Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

  NCT00826020

  Conditions:   Parenteral Nutrition Associated Liver Disease PNALD;   Cholestasis
  Intervention:   Drug: Omegaven™
  Sponsor:   University of Nebraska
  Completed
• Specialized Substance Abuse Supervision (SSAS) Versus Non-SSAS Recidivism Rates Among Nebraska Felony Drug Offenders

  NCT00690352

  Conditions:   Substance-related Disorders;   Alcohol-related Disorders
  Intervention:   Behavioral: Specialized Substance Abuse Supervision (SSAS)
  Sponsor:   University of Nebraska
  Completed
• Self-Management App for Patients With Left-Ventricular Assist Devices

  NCT03049748

  Condition:   Heart Failure
  Interventions:   Device: Mobile phone app (VAD Care App);   Other: Usual LVAD Care
  Sponsors:   University of Michigan;   Washington University School of Medicine;   National Institute of Nursing Research (NINR)
  Completed
• Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

  NCT02062632

  Conditions:   Esophageal Carcinoma;   Hypopharyngeal Carcinoma;   Laryngeal Carcinoma;   Lymphoma;   Mesothelioma;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pleura;   Metastatic Malignant Neoplasm in the Spinal Cord;   Non-Small Cell Lung Carcinoma;   Sarcoma;   Small Cell Lung Carcinoma;   Thymic Carcinoma;   Thymoma;   Thyroid Gland Carcinoma
  Interventions:   Drug: Doxepin Hydrochloride;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Terminated
• Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

  NCT03598998

  Conditions:   Anaplastic Large Cell Lymphoma;   Nodal Peripheral T-Cell Lymphoma With TFH Phenotype;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Angioimmunoblastic T-Cell Lymphoma;   Recurrent Enteropathy-Associated T-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hepatosplenic T-Cell Lymphoma;   Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Angioimmunoblastic T-Cell Lymphoma;   Refractory Enteropathy-Associated T-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Hepatosplenic T-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Subcutaneous Panniculitis-Like T-Cell Lymphoma
  Interventions:   Biological: Pembrolizumab;   Drug: Pralatrexate
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma

  NCT03534180

  Conditions:   Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Venetoclax
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That Is Resistant to Chemotherapy

  NCT01035463

  Conditions:   Anaplastic Large Cell Lymphoma, ALK-Negative;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma
  Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Lenalidomide;   Drug: Melphalan;   Biological: Rituximab
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Completed
• Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer

  NCT01880528

  Conditions:   Dyspnea;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer
  Interventions:   Drug: lisinopril;   Drug: placebo
  Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
  Active, not recruiting
• Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

  NCT01431209

  Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Ruxolitinib Phosphate
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Active, not recruiting
• Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

  NCT00717522

  Condition:   Soft Tissue Sarcoma
  Intervention:   Drug: Pomalidomide
  Sponsor:   Celgene
  Terminated
• Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

  NCT04064905

  Condition:   Zika Virus
  Interventions:   Biological: mRNA-1893;   Other: Placebo
  Sponsors:   ModernaTX, Inc.;   Biomedical Advanced Research and Development Authority
  Recruiting
• Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

  NCT04067011

  Condition:   Anthrax
  Interventions:   Drug: Ciprofloxacin 500Mg Tablet;   Drug: Doxycycline 100Mg Tablet;   Biological: AV7909
  Sponsors:   Emergent Product Development Gaithersburg, Inc.;   Biomedical Advanced Research and Development Authority
  Recruiting
• Validation of Patient Reported Outcome Measures for Use in Vulvodynia

  NCT03770169

  Condition:   Vulvodynia
  Intervention:  
  Sponsor:   Ipsen
  Completed
• Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids

  NCT03616184

  Condition:   Graft-versus-host-disease (GVHD)
  Intervention:   Drug: Ruxolitinib
  Sponsor:   University of Nebraska
  Recruiting
• HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection

  NCT03575910

  Conditions:   Heart Transplant Failure and Rejection;   Heart Failure;   Heart Diseases;   Heart Failure，Congestive;   Transplant; Failure, Heart;   Transplant Failure
  Intervention:  
  Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR);   PROOF Centre of Excellence;   Duke University;   University of Nebraska;   Toronto General Hospital;   St. Paul's Hospital, Canada
  Recruiting
• Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program

  NCT02673255

  Condition:   Healthy
  Intervention:   Biological: Tetanus and Diphtheria (Td) Vaccine
  Sponsors:   Biomat USA, Inc.;   Hammond Clinical Trial Consulting, LLC;   Axio Research. LLC
  Active, not recruiting
• Smith-Lemli-Opitz Syndrome and Cholic Acid

  NCT03720990

  Condition:   Smith-Lemli-Opitz Syndrome
  Intervention:   Drug: Cholic Acid
  Sponsors:   University of Nebraska;   University of Colorado, Denver;   Children's Hospital Medical Center, Cincinnati;   University of Pittsburgh
  Not yet recruiting
• A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

  NCT02990468

  Condition:   Head and Neck Cancer
  Interventions:   Drug: BMX-001;   Radiation: Radiation Therapy;   Drug: Cisplatin
  Sponsors:   BioMimetix JV, LLC;   Duke University
  Recruiting
• A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas

  NCT03316573

  Conditions:   Lymphoma;   Histiocytic Sarcoma;   Follicular Dendritic Cell Sarcoma;   Interdigitating Dendritic Cell Sarcoma
  Intervention:   Drug: Pembrolizumab
  Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
  Recruiting
• A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

  NCT02967133

  Conditions:   Non-Small-Cell Lung Cancer Metastatic;   Non-Small Cell Carcinoma of Lung, TNM Stage 4;   Nonsmall Cell Lung Cancer;   Non Small Cell Lung Cancer Recurrent
  Interventions:   Drug: Nivolumab;   Drug: nab-paclitaxel
  Sponsors:   Alliance Foundation Trials, LLC.;   Celgene Corporation;   Bristol-Myers Squibb
  Active, not recruiting
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

  NCT02445911

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: KQ-791;   Drug: Placebo
  Sponsor:   Kaneq Bioscience Limited
  Completed
• ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

  NCT00477529

  Condition:   Hormone Refractory Prostate Cancer
  Intervention:   Drug: ABI-008
  Sponsor:   Celgene
  Completed
• A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

  NCT04032093

  Condition:   Respiratory Tract Infection
  Interventions:   Biological: RSV vaccine;   Biological: Placebo
  Sponsor:   Pfizer
  Recruiting
• Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

  NCT03828617

  Condition:   Pneumococcal Disease
  Interventions:   Biological: 20vPnC;   Biological: 13vPnC
  Sponsor:   Pfizer
  Completed
• LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

  NCT03412890

  Conditions:   Heavy Menstrual Bleeding;   Uterine Fibroid
  Interventions:   Drug: Relugolix;   Drug: Estradiol/norethindrone acetate
  Sponsor:   Myovant Sciences GmbH
  Active, not recruiting
• Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults

  NCT03301051

  Conditions:   Virus Diseases;   RNA Virus Infections;   Respiratory Tract Diseases;   Respiratory Tract Infections
  Interventions:   Biological: Quadrivalent VLP Vaccine;   Biological: Placebo
  Sponsor:   Medicago
  Completed
• Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  NCT03150693

  Condition:   B Acute Lymphoblastic Leukemia
  Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated L-Asparaginase;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

  NCT03049735

  Conditions:   Heavy Menstrual Bleeding;   Uterine Fibroid
  Interventions:   Drug: Relugolix;   Drug: Estradiol/norethindrone acetate;   Drug: Placebo for E2/NETA;   Drug: Placebo for relugolix
  Sponsor:   Myovant Sciences GmbH
  Active, not recruiting
• A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

  NCT03311555

  Condition:   Prostate Cancer
  Interventions:   Drug: Apalutamide;   Drug: Androgen deprivation;   Radiation: Salvage radiation therapy;   Drug: Docetaxel
  Sponsor:   Tian Zhang, MD
  Recruiting
• A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

  NCT02624947

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Biological: RSV F vaccine with adjuvant;   Biological: Formulation buffer
  Sponsors:   Novavax;   Bill and Melinda Gates Foundation
  Completed
• Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

  NCT04003103

  Condition:   HIV-1 Infection
  Interventions:   Drug: Islatravir;   Drug: Placebo
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

  NCT03520517

  Conditions:   Amyotrophic Lateral Sclerosis;   ALS;   Lou Gehrig Disease;   Lou Gehrig's Disease;   Lou-Gehrigs Disease;   Motor Neuron Disease, Amyotrophic Lateral Sclerosis
  Intervention:   Drug: BHV-0223
  Sponsors:   Biohaven Pharmaceuticals, Inc.;   Cognitive Research Corporation
  Completed
• Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology

  NCT03699514

  Conditions:   Healthy;   Cognitive Impairment;   Neurological Disorder
  Intervention:   Device: Brain Network Activation (BNA™) technology
  Sponsor:   ElMindA Ltd
  Recruiting
• PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

  NCT04142658

  Conditions:   Aortic Valve Disease;   Aortic Valve Stenosis;   Aortic Valve Failure
  Interventions:   Drug: Apixaban 5 MG;   Drug: Apixaban 2.5 MG;   Drug: Warfarin;   Device: On-X Aortic Mechanical Valve
  Sponsors:   CryoLife, Inc.;   Duke Clinical Research Institute
  Not yet recruiting
• A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation

  NCT04029545

  Condition:   Lip Augmentation
  Intervention:   Device: PN40082
  Sponsors:   Prollenium Medical Technologies Inc.;   Symbio, LLC
  Active, not recruiting
• High Dose IL 2 and Entinostat in RCC

  NCT03501381

  Condition:   Renal Cell Carcinoma
  Interventions:   Drug: Entinostat;   Drug: Interleukin-2
  Sponsors:   Roberto Pili;   Indiana University Melvin and Bren Simon Cancer Center;   Prometheus Laboratories;   Syndax Pharmaceuticals
  Recruiting
• Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer

  NCT04095364

  Conditions:   Low Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal Low Grade Serous Adenocarcinoma;   Stage II Ovarian Cancer AJCC v8;   Stage IIA Ovarian Cancer AJCC v8;   Stage IIB Ovarian Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Drug: Letrozole;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474

  Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Guiding Treatment for Patients With Brain Metastases

  NCT03994796

  Conditions:   CDK Gene Mutation;   Metastatic Malignant Neoplasm in the Brain;   Metastatic Malignant Solid Neoplasm;   NTRK Family Gene Mutation;   PI3K Gene Mutation;   ROS1 Gene Mutation
  Interventions:   Drug: Abemaciclib;   Drug: PI3K Inhibitor GDC-0084;   Drug: Entrectinib
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Genentech, Inc.
  Recruiting
• Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  NCT03937635

  Condition:   Smoldering Plasma Cell Myeloma
  Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445

  Condition:   Previously Treated Non-Small Cell Lung Cancer
  Intervention:   Drug: Screening Platform
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382

  Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

  NCT03793166

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
  Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414

  Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)

  NCT03737994

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer

  NCT03811015

  Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

  NCT03723928

  Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8;   Elevated CA15-3 or CEA or CA27-29
  Interventions:   Other: Usual care disease monitoring;   Other: Serum Tumor Marker directed disease monitoring;   Other: Quality-of-Life Assessment;   Other: Anxiety Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

  NCT03698019

  Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

  NCT03701282

  Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

  NCT03694002

  Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer

  NCT03660826

  Conditions:   Endometrial Undifferentiated Carcinoma;   Endometrioid Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Drug: Cediranib;   Drug: Cediranib Maleate;   Drug: Olaparib
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia

  NCT03654768

  Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

  NCT03839940

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Dexamethasone;   Other: Placebo;   Other: Questionnaire;   Other: Quality-of-Life Assessment;   Drug: Everolimus
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab and Epacadostat in Treating Patients With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma

  NCT03602586

  Conditions:   Malignant Ovarian Clear Cell Tumor;   Recurrent Ovarian Carcinoma
  Interventions:   Drug: Epacadostat;   Biological: Pembrolizumab
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Suspended
• Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

  NCT03609216

  Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
  Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

  NCT03499808

  Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
  Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

  NCT03468985

  Conditions:   Metastatic Lung Non-Squamous Non-Small Cell Carcinoma;   Recurrent Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

  NCT03414970

  Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
  Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

  NCT03418961

  Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561

  Conditions:   Extensive Stage Lung Small Cell Carcinoma;   Recurrent Lung Small Cell Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

  NCT03578081

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882

  Conditions:   Colon Adenocarcinoma;   ERBB2 Gene Amplification;   Rectal Adenocarcinoma;   Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage III Colon Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIA Rectal Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIB Rectal Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7;   Stage IIIC Rectal Cancer AJCC v7;   Stage IV Colon Cancer AJCC v7;   Stage IV Rectal Cancer AJCC v7;   Stage IVA Colon Cancer AJCC v7;   Stage IVA Rectal Cancer AJCC v7;   Stage IVB Colon Cancer AJCC v7;   Stage IVB Rectal Cancer AJCC v7
  Interventions:   Biological: Cetuximab;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Biological: Trastuzumab;   Device: HER-2 testing
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

  NCT03228537

  Conditions:   Biphasic Mesothelioma;   Epithelioid Mesothelioma;   Stage I Pleural Malignant Mesothelioma AJCC v7;   Stage IA Pleural Malignant Mesothelioma AJCC v7;   Stage IB Pleural Malignant Mesothelioma AJCC v7;   Stage II Pleural Malignant Mesothelioma AJCC v7;   Stage III Pleural Malignant Mesothelioma AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Cisplatin;   Procedure: Extrapleural Pneumonectomy;   Drug: Pemetrexed Disodium;   Procedure: Pleurectomy;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

  NCT03087708

  Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
  Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674

  Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2
  Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Advanced Melanoma;   Melanoma of Unknown Primary;   Mucosal Melanoma;   Refractory Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

  NCT03018249

  Conditions:   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma;   Uterine Corpus Adenosarcoma
  Interventions:   Drug: Entinostat;   Procedure: Hysterectomy;   Other: Laboratory Biomarker Analysis;   Drug: Medroxyprogesterone Acetate
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men

  NCT03518034

  Conditions:   Hypogonadism;   Cardiovascular Diseases
  Interventions:   Drug: Testosterone;   Drug: Placebo
  Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

  NCT02921256

  Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
  Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Suspended
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

  NCT02890355

  Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
  Interventions:   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

  NCT02893930

  Conditions:   Pancreatic Neuroendocrine Tumor G1;   Pancreatic Neuroendocrine Tumor G2;   Refractory Pancreatic Neuroendocrine Carcinoma
  Intervention:   Drug: Sapanisertib
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02839707

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Undifferentiated Carcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Suspended
• Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

  NCT02834013

  Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Angiosarcoma;   Apocrine Neoplasm;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Basal Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cervical Clear Cell Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Extramammary Paget Disease;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gallbladder Carcinoma;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Gestational Trophoblastic Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   PEComa;   Peritoneal Mesothelioma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Solid Neoplasm;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Somatic-Type Malignancy;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
  Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer

  NCT03304639

  Conditions:   Stage III Merkel Cell Carcinoma AJCC v7;   Stage IIIA Merkel Cell Carcinoma AJCC v7;   Stage IIIB Merkel Cell Carcinoma AJCC v7;   Stage IV Merkel Cell Carcinoma AJCC v7
  Interventions:   Biological: Pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

  NCT02734537

  Conditions:   Head and Neck Squamous Cell Carcinoma;   Hypopharyngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma;   Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant;   Lip and Oral Cavity Squamous Cell Carcinoma;   p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

  NCT02761057

  Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

  NCT02601209

  Conditions:   High Grade Sarcoma;   Metastatic Leiomyosarcoma;   Metastatic Malignant Peripheral Nerve Sheath Tumor;   Metastatic Synovial Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Metastatic Unresectable Sarcoma;   Myxofibrosarcoma;   Recurrent Leiomyosarcoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Synovial Sarcoma;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Stage III Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IV Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8;   Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8;   Unresectable Leiomyosarcoma
  Interventions:   Drug: Pazopanib;   Drug: Pazopanib Hydrochloride;   Drug: Sapanisertib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905

  Conditions:   Breast Carcinoma Metastatic in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas

  NCT02523014

  Conditions:   Intracranial Meningioma;   Recurrent Meningioma;   NF2 Gene Mutation
  Interventions:   Drug: vismodegib;   Drug: GSK2256098
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   GlaxoSmithKline;   Genentech, Inc.;   Brain Science Foundation
  Suspended
• High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

  NCT02506153

  Conditions:   Metastatic Cutaneous Melanoma;   Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Cutaneous Melanoma;   Recurrent Non-Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage III Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
  Interventions:   Biological: Ipilimumab;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

  NCT02500797

  Conditions:   Dedifferentiated Liposarcoma;   Gastrointestinal Stromal Tumor;   Locally Advanced Bone Sarcoma;   Locally Advanced Soft Tissue Sarcoma;   Metastatic Bone Sarcoma;   Metastatic Liposarcoma;   Metastatic Soft Tissue Sarcoma;   Metastatic Undifferentiated Pleomorphic Sarcoma;   Metastatic Unresectable Sarcoma;   Pleomorphic Liposarcoma;   Stage III Bone Sarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Bone Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Bone Sarcoma AJCC v7;   Stage IVB Bone Sarcoma AJCC v7;   Unresectable Bone Sarcoma;   Unresectable Liposarcoma;   Unresectable Soft Tissue Sarcoma
  Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT02498600

  Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944

  Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Intervention:   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer

  NCT02466971

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Stage IB2 Cervical Cancer AJCC v6 and v7;   Stage II Cervical Cancer AJCC v7;   Stage II Vaginal Cancer AJCC v6 and v7;   Stage IIA Cervical Cancer AJCC v7;   Stage IIB Cervical Cancer AJCC v6 and v7;   Stage III Vaginal Cancer AJCC v6 and v7;   Stage IIIB Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVA Vaginal Cancer AJCC v6 and v7;   Vaginal Adenocarcinoma;   Vaginal Adenosquamous Carcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
  Interventions:   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: Triapine
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

  NCT02311933

  Conditions:   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tamoxifen Citrate;   Drug: Z-Endoxifen Hydrochloride
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

  NCT02257528

  Conditions:   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Recurrent Cervical Carcinoma;   Stage IV Cervical Cancer AJCC v6 and v7;   Stage IVA Cervical Cancer AJCC v6 and v7;   Stage IVB Cervical Cancer AJCC v6 and v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

  NCT02224781

  Conditions:   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

  NCT02196181

  Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

  NCT02164916

  Condition:   Colorectal Cancer
  Interventions:   Biological: cetuximab;   Drug: irinotecan hydrochloride;   Drug: vemurafenib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Roche-Genentech
  Active, not recruiting
• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

  NCT02154490

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Other: Pharmacological Study;   Biological: Rilotumumab;   Drug: Talazoparib;   Drug: Taselisib;   Biological: Tremelimumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib

  NCT02134912

  Conditions:   Adenocarcinoma of the Lung;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
  Interventions:   Drug: crizotinib;   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Terminated
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

  NCT02152982

  Conditions:   Glioblastoma;   Gliosarcoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Temozolomide;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788

  Conditions:   Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Low Grade Ovarian Serous Adenocarcinoma;   Recurrent Primary Peritoneal Serous Adenocarcinoma
  Interventions:   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen;   Drug: Tamoxifen Citrate;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Trametinib;   Drug: Trametinib Dimethyl Sulfoxide
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

  NCT02066181

  Condition:   Desmoid-Type Fibromatosis
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT02048813

  Conditions:   Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
  Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Biological: Rituximab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

  NCT02003209

  Conditions:   HER2/Neu Positive;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
  Interventions:   Drug: Aromatase Inhibition Therapy;   Drug: Carboplatin;   Other: Cytology Specimen Collection Procedure;   Drug: Docetaxel;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Quality-of-Life Assessment;   Procedure: Therapeutic Conventional Surgery;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Active, not recruiting
• Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

  NCT01953588

  Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
  Interventions:   Drug: fulvestrant;   Drug: anastrozole
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• Integrated Cancer Repository for Cancer Research

  NCT02012699

  Conditions:   Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breast Cancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer;   Neuroendocrine Tumors;   Plasma Cell Dyscrasia;   Healthy Control
  Intervention:  
  Sponsor:   University of Nebraska
  Recruiting
• Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01950390

  Conditions:   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Biological: Bevacizumab;   Biological: Ipilimumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

  NCT02032823

  Condition:   Breast Cancer
  Interventions:   Drug: Olaparib;   Drug: Placebo
  Sponsors:   AstraZeneca;   Breast International Group;   Frontier Science & Technology Research Foundation, Inc.;   NRG Oncology;   Myriad Genetic Laboratories, Inc.;   Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet;   Merck Sharp & Dohme Corp.
  Active, not recruiting
• Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

  NCT01896999

  Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
  Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

  NCT02924727

  Condition:   Acute Myocardial Infarction
  Interventions:   Drug: LCZ696 (sacubitril/valsartan);   Drug: Ramipril;   Drug: Placebo of LCZ696;   Drug: Placebo of ramipril;   Drug: Valsartan;   Drug: Placebo of valsartan
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT01863550

  Condition:   Plasma Cell Myeloma
  Interventions:   Drug: Bortezomib;   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Active, not recruiting